Business News • PR NewsWire • Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA

Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA

Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA

SAN DIEGO, Oct. 23 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) announced today the presentation of combined data from its two fidaxomicin Phase 3 trials in patients with Clostridium difficile infection (CDI) at the 48th Annual Meeting of the Infectious Disease Society of America (ID

View More : http://www.prnewswire.com/news-releases/optimer-pharmaceuticals-announces-combined-data-from-fidaxomicin-phase-3-trials-...

Releted News by prnewswire

Mayor Johnson Joins Dr. Mehmet Oz, California Walnut Board in Launching of HealthCorps® in Sacramento

New York Residence Offers Apartments in Landmarked Skyscraper at Unmatched Prices

South Central Ohio MSDC Celebrates 38th Annual Awards Gala, Featuring Mr. Ed Gordon of BET

National Mortgage Forensic Loan Auditors - NMFLA.com, Featured Real Estate Loan Audit Firm to Attorneys and Bankers Established Consumer Presence.

Prima Edizione Fiat 500 Auctioned at National Italian American Foundation's 35th Anniversary Gala